Aeglea BioTherapeutics, Inc. Initial Public Offering

Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $54.8 million initial public offering by Aeglea BioTherapeutics, Inc. Aeglea’s common stock is listed on the NASDAQ Global Market under the symbol “AGLE.”

Based in Austin, Texas, Aeglea is a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer.

The Davis Polk corporate team included partner Bruce K. Dallas, counsel Jeffrey Gould and associate Keerthika Melissa Subramanian. The tax team included partner Rachel D. Kleinberg and associate Alexander Wu. The intellectual property and technology team included associates Michelle Gross and Jason J. Bang. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California and New York offices.